Literature DB >> 1375196

Monoclonal antibodies define genus-specific, species-specific, and cross-reactive epitopes of the chlamydial 60-kilodalton heat shock protein (hsp60): specific immunodetection and purification of chlamydial hsp60.

Y Yuan1, K Lyng, Y X Zhang, D D Rockey, R P Morrison.   

Abstract

Ocular and urogenital tract infections with Chlamydia trachomatis can progress to chronic inflammatory diseases that produce blindness and tubal infertility. The pathophysiology of these chronic disease conditions is thought to be immunologically mediated, and the chlamydial 60-kDa heat shock protein (hsp60) has been implicated as a major target antigen that stimulates the immunopathological response. The lack of chlamydial hsp60 antibodies and purified hsp60 has severely restricted studies to define more thoroughly the role of this protein in the immunopathogenesis of chlamydial disease. We produced a panel of antichlamydial hsp60 monoclonal antibodies (MAbs) and defined their specificities by immunoblotting against lysates of C. trachomatis, C. psittaci, and six other genera of bacteria. Three patterns of anti-hsp60 immunoreactivity were observed: chlamydial species specific, chlamydial genus specific, and cross-reactive. The epitopes recognized by these MAbs were localized within the primary amino acid sequence of hsp60 by immunoblotting against recombinant amino-terminal truncated hsp60 fusion polypeptides and then precisely mapped by use of overlapping synthetic peptides. The majority of the MAbs mapped to either the amino or the carboxyl termini of hsp60. Epitopes defining all three MAb reactivities mapped within amino-terminal residues 6 to 16. Genus-specific hsp60 MAbs mapped to epitopes located within this region and to residues 17 to 28 and 177 to 189. Antichlamydial hsp60 MAbs stained inclusions as effectively as MAbs specific for the major outer membrane protein. Homogeneous preparations of full-length recombinant chlamydial hsp60 and amino-terminal truncated recombinant hsp60 polypeptides were obtained by immunoabsorption chromatography with an hsp60 MAb reactive to the carboxyl terminus of the protein. Thus, the antichlamydial MAbs described here should be extremely useful for the specific immunodetection of hsp60 in tissues from individuals having different disease manifestations and for the purification of hsp60 or truncated hsp60 polypeptides for use in serologic and lymphocyte proliferation assays. The availability of these MAbs will facilitate studies to define more precisely the role of hsp60 in the immunopathogenesis of chlamydial disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375196      PMCID: PMC257156          DOI: 10.1128/iai.60.6.2288-2296.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  T cells and trachoma. Their role in cicatricial disease.

Authors:  M H Reacher; J Pe'er; P A Rapoza; J A Whittum-Hudson; H R Taylor
Journal:  Ophthalmology       Date:  1991-03       Impact factor: 12.079

Review 2.  Chlamydial hsp60 and the immunopathogenesis of chlamydial disease.

Authors:  R P Morrison
Journal:  Semin Immunol       Date:  1991-01       Impact factor: 11.130

3.  The Chlamydia trachomatis hyp operon is homologous to the groE stress response operon of Escherichia coli.

Authors:  R P Morrison; H Su; K Lyng; Y Yuan
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

4.  Protective monoclonal antibodies to Chlamydia trachomatis serovar- and serogroup-specific major outer membrane protein determinants.

Authors:  Y X Zhang; S J Stewart; H D Caldwell
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

5.  Conjunctival lymphocyte subsets in trachoma.

Authors:  E M Burd; K F Tabbara; A M Nasr; P B Taylor
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

6.  Differential human serologic response to two 60,000 molecular weight Chlamydia trachomatis antigens.

Authors:  E A Wagar; J Schachter; P Bavoil; R S Stephens
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

7.  Interferon-gamma in endocervical secretions of women infected with Chlamydia trachomatis.

Authors:  J N Arno; V A Ricker; B E Batteiger; B P Katz; V A Caine; R B Jones
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

8.  Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen.

Authors:  S Jindal; A K Dudani; B Singh; C B Harley; R S Gupta
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

9.  T cell and antibody reactivity with the Borrelia burgdorferi 60-kDa heat shock protein in Lyme arthritis.

Authors:  M C Shanafelt; P Hindersson; C Soderberg; N Mensi; C W Turck; D Webb; H Yssel; G Peltz
Journal:  J Immunol       Date:  1991-06-01       Impact factor: 5.422

10.  Chlamydial disease pathogenesis. The 57-kD chlamydial hypersensitivity antigen is a stress response protein.

Authors:  R P Morrison; R J Belland; K Lyng; H D Caldwell
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

View more
  36 in total

1.  Chlamydial serology: comparative diagnostic value of immunoblotting, microimmunofluorescence test, and immunoassays using different recombinant proteins as antigens.

Authors:  S Bas; P Muzzin; B Ninet; J E Bornand; C Scieux; T L Vischer
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Chlamydia pneumoniae in vitro and in vivo: a critical evaluation of in situ detection methods.

Authors:  A Meijer; P J Roholl; S K Gielis-Proper; Y F Meulenberg; J M Ossewaarde
Journal:  J Clin Pathol       Date:  2000-12       Impact factor: 3.411

3.  Identification of an antigen localized to an apparent septum within dividing chlamydiae.

Authors:  W J Brown; D D Rockey
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

4.  Chlamydial antigens colocalize within IncA-laden fibers extending from the inclusion membrane into the host cytosol.

Authors:  W J Brown; Y A W Skeiky; P Probst; D D Rockey
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

5.  Analysis of putative Chlamydia trachomatis chaperones Scc2 and Scc3 and their use in the identification of type III secretion substrates.

Authors:  Kenneth A Fields; Elizabeth R Fischer; David J Mead; Ted Hackstadt
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

6.  Chlamydial GroEL autoregulates its own expression through direct interactions with the HrcA repressor protein.

Authors:  Adam C Wilson; Christine C Wu; John R Yates; Ming Tan
Journal:  J Bacteriol       Date:  2005-11       Impact factor: 3.490

7.  Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle.

Authors:  K Wolf; H J Betts; B Chellas-Géry; S Hower; C N Linton; K A Fields
Journal:  Mol Microbiol       Date:  2006-09       Impact factor: 3.501

8.  Reactivation of persistent Chlamydia trachomatis infection in cell culture.

Authors:  W L Beatty; R P Morrison; G I Byrne
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

9.  Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection.

Authors:  R P Morrison; K Feilzer; D B Tumas
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.

Authors:  Y Han; R P Morrison; J E Cutler
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.